Plasma cell neoplasm

This study looked at whether the HPV vaccine works in girls aged 9 to 17 who are taking medicines that weaken their immune system, such as after an organ transplant or for diseases like lupus. The goal was to see if their bodies produce enough antibodies to protect against HPV. T…

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This early-phase trial tested a personalized vaccine made from each patient's own blood and bone marrow. The goal was to help the immune system recognize and kill cancer cells in people with smoldering multiple myeloma, a pre-cancer condition. The study involved 30 adults at high…

This early-phase trial tested whether giving patients their own natural killer (NK) cells, boosted by the drug bortezomib, is safe for treating advanced cancers like leukemia, lung, and pancreatic cancer. Thirty-five adults whose cancers had not responded to standard treatments r…

This study tests whether a secure website with educational sessions, goal-setting, and tracking tools can help survivors of several cancers (including breast, prostate, colorectal, and others) improve their diet, increase physical activity, and manage weight. Participants are age…

This early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…

This study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…

This early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…

This early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-phase study tests a new treatment for multiple myeloma that has returned or stopped responding to prior therapies. It combines specially engineered natural killer (NK) cells (called TiNK) with an antibody drug (isatuximab) and standard chemotherapy. The main goal is to…

This early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…

This study tests a drug called acalabrutinib in Japanese adults with advanced B-cell blood cancers (like leukemia and lymphoma). The goal is to see if it is safe and helps control the cancer. Participants take the drug daily, and researchers monitor side effects and how well the …

This pilot study tested whether the multiple myeloma drug carfilzomib can be safely given at home instead of in a hospital. Seventeen patients received their first cycle in the clinic and later cycles at home, with nurses administering the short infusion. The main goal was to see…

This early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …

This phase 2 trial tested nivolumab, an immunotherapy drug, in 20 people with blood cancers like lymphoma, leukemia, or myeloma that came back or didn't respond after CAR T-cell therapy. The goal was to see if nivolumab could help the immune system attack the cancer again. The st…

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…

This phase 3 trial is testing whether adding daratumumab (a targeted antibody) to standard lenalidomide maintenance therapy can clear remaining cancer cells in people with multiple myeloma who still have minimal residual disease after a stem cell transplant. About 200 participant…

This phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…

This early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…

This study tested a drug called ixazomib, alone or with other medicines, in 165 people whose multiple myeloma (a blood cancer) had come back. The goal was to see if these combinations could shrink or control the cancer. Participants received different treatment plans, and doctors…

This Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…

This phase 3 trial tests whether a personalized cell therapy called bb2121 works better than standard drug combinations for people with relapsed and refractory multiple myeloma. About 386 participants were randomly assigned to receive either bb2121 or one of several standard regi…

This trial tests omidubicel, an experimental stem cell transplant, for people with high-risk blood cancers like leukemia or lymphoma. The goal is to see if it helps the body rebuild its immune system faster after transplant. Participants receive omidubicel along with standard tra…

This study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …

This early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…

This phase II trial tested the drug imetelstat in 13 patients with multiple myeloma who had stable disease or partial response after prior therapy but not a complete remission. The goal was to see if adding imetelstat could improve their response. Patients received imetelstat int…

This study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…

This study looked at whether denosumab, a drug usually used for bone health, could safely reduce the risk of smoldering multiple myeloma turning into active multiple myeloma. Twenty people with smoldering multiple myeloma took part. The goal was to see if the drug could lower the…

This study tested two drug combinations in 186 adults with multiple myeloma that came back or didn't respond after earlier treatment. One group got pomalidomide plus low-dose dexamethasone, and another got those two plus daratumumab. The goal was to see if the tumors shrank enoug…

This pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …

This early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This trial studies a combination of the investigational antibody isatuximab with the drugs carfilzomib and dexamethasone for people with multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find the safest dose and see how well the body…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…

This phase 3 study tested whether the drug daratumumab, given as a shot under the skin, could delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. 390 people with high-risk smoldering myeloma were randomly assigned to receive daratumumab or to b…

This early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…

This study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…

This early-phase study tested whether specially grown immune cells (cytokine-induced killer cells) could safely treat blood cancers that return after a stem cell transplant. 21 adults with relapsed multiple myeloma or other blood cancers received these donor cells. The goal was t…

This phase 2 study tested a combination of two chemotherapy drugs, busulfan and melphalan, given before an autologous stem cell transplant in 78 people with newly diagnosed multiple myeloma. All participants had already received a bortezomib-based induction therapy and then took …

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This study tested teclistamab, a drug that helps the immune system find and attack myeloma cells, in 40 Japanese patients whose multiple myeloma had returned or stopped responding to treatment. The goal was to check safety and find the right dose in phase 1, then see how well it …

This study tested whether the drug siltuximab can lessen the severity of cytokine release syndrome (CRS) and neurological side effects (ICANS) that often occur after CAR-T cell therapy for blood cancers like lymphoma and leukemia. Twenty-four participants received siltuximab alon…

This phase 3 study tested whether adding daratumumab to a standard three-drug regimen (bortezomib, lenalidomide, dexamethasone) helps people with newly diagnosed multiple myeloma who are not candidates for stem cell transplant. The main goal was to see if more patients achieve a …

This early-stage trial tested an experimental drug called SAR442257 in 47 adults with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might fight t…

This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.

This early-phase trial tested a combination of two drugs—selinexor and choline salicylate (a type of aspirin)—in 22 adults with certain lymphomas or multiple myeloma that had come back or not responded to treatment. The main goal was to find the safest dose and check for side eff…

This early-phase study tested whether the oral antibiotic rifaximin can reduce abnormal proteins in people with monoclonal gammopathy, a condition that can lead to blood cancers. Fifty adults with different types of gammopathy took the drug to see if it lowered their immunoglobul…

This early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…

This early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…

This study tested a treatment called anti-BCMA CAR T-cell therapy in 40 adults with multiple myeloma whose disease did not respond well enough to a stem cell transplant and maintenance therapy. The goal was to see if this one-time cell therapy could help more patients achieve a c…

This phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for s…

This study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…

This early-phase study tested a new drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like chronic lymphocytic leukemia). The main goals were to check the drug's safety and how the body processes it. Researchers looked for side effects and measured drug l…

This early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims …

This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease…

This early-phase study tested a new type of CAR T cell therapy, called ALLO-715, made from donor cells (not the patient's own). It was given to 73 adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The goal was to check safet…

This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed tha…

This study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…

This early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…

This early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …

This early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…

This study tested a daily supplement of curcumin (from turmeric) and piperine (from black pepper) in 30 people with early-stage prostate cancer or pre-cancerous blood conditions (MGUS or low-risk smoldering multiple myeloma). The goal was to see if the supplement could lower canc…

This study looked at how safe and tolerable the drug Kyprolis is for Indian patients whose multiple myeloma has come back or stopped responding to treatment. A total of 101 adults took part, and researchers tracked side effects and how long the drug kept the cancer from getting w…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study tested whether a special oral nutritional supplement (Ensure Complete) could help patients with blood cancer maintain weight and gut health after a stem cell transplant. One hundred participants were randomly assigned to receive either the supplement or a standard hosp…

This early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…

This study tested a two-step treatment for people whose multiple myeloma returned after a donor stem cell transplant. First, patients received lenalidomide and dexamethasone to reduce cancer and prepare the immune system. Then, they received donor immune cells (lymphocyte infusio…

This early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…

This study tested different dosing schedules of the drug belantamab mafodotin in 177 adults with multiple myeloma that had returned or stopped responding to at least three prior treatments. The goal was to see if changing the dose or how often it is given could reduce serious eye…

This study tested a new way to deliver total body radiation to adults with blood cancers who need a stem cell transplant. The goal was to see if this method could effectively target cancer while protecting the lungs. 36 patients took part, and the study focused on safety and how …

This study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.

This phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…

This study tested a new drug called REGN5459 in 43 people with multiple myeloma that had returned or stopped responding to other treatments. The drug works by helping the immune system attack cancer cells. The main goals were to check safety and find the best dose, and to see how…

This study tested a drug called daratumumab in 49 people with multiple myeloma who were eligible for a stem cell transplant. The goal was to see if daratumumab could help eliminate any remaining cancer cells in the bone marrow after the transplant. While the treatment aims to con…

This early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…

This study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…

This study tested different drug combinations to prevent graft-versus-host disease (GVHD) in 174 people with blood cancers receiving stem cells from an unrelated donor. GVHD is a serious side effect where donor cells attack the patient's body. The goal was to find which drug regi…

This study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…

This study tested adding elotuzumab to a standard three-drug combination (bortezomib, lenalidomide, dexamethasone) for people newly diagnosed with high-risk multiple myeloma, a blood cancer that tends to come back quickly. The goal was to find the safest dose of elotuzumab and se…

This completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This phase 2 trial tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—given before and after a stem cell transplant in 76 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep remission (stringent co…

This study tested whether a drug called alpha-1 antitrypsin (AAT) can prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD occurs when donor immune cells attack the patient's body. The trial enrolled 222 participants and compa…

This phase 2 trial tested three different schedules of the drug daratumumab in 123 people with smoldering multiple myeloma, a condition that often progresses to active multiple myeloma. The goal was to see how well each schedule controlled the disease and led to complete response…

This early-phase study tested whether giving specially selected donor immune cells (NK cells) soon after a stem cell transplant is safe for people with blood cancers. Seventeen patients received the cells, and researchers monitored for serious side effects within 30 days. The goa…

This early study tested the drug belimumab (Benlysta) to see if it could prevent chronic graft-versus-host disease (GvHD) in 10 adults who had a stem cell transplant for blood cancer. GvHD is a serious condition where the donor's immune cells attack the patient's body. The main g…

This early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…

This study looked at whether giving the antibiotic vancomycin helps cancer patients who have diarrhea and a positive screening test for C. difficile but a negative toxin test. Only 9 patients were enrolled, far fewer than planned. Researchers measured changes in C. difficile leve…

This study tested different combinations of cancer drugs (carfilzomib, cyclophosphamide, lenalidomide, and dexamethasone) in 477 adults newly diagnosed with multiple myeloma who were eligible for a stem cell transplant. The goal was to see which combination worked best before and…

This study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…

This study offers continued treatment with elotuzumab (plus dexamethasone) to 67 multiple myeloma patients who were already benefiting from it in earlier trials. The main goal is to keep providing the drug and track how long patients stay on treatment. Researchers will also monit…

This phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…

This phase 2 study tested whether the drug romiplostim can prevent severe low platelet counts caused by chemotherapy in people with lymphoma. Eleven adult patients received weekly injections of romiplostim during their 21-day chemo cycles. The goal was to see if it could reduce t…

This early-stage trial tested a new drug called forimtamig in 225 people with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to check safety and find the right dose. Participants received the drug by IV or injection, and resea…

This study tested whether adding the drug bortezomib to the standard chemotherapy before a donor stem cell transplant could help people with multiple myeloma live longer without their cancer getting worse. Fifty-four adults received the new drug combo. The main goal was to see if…

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could le…

This phase 1b trial tested the safety of adding TAK-079 (Mezagitamab) to standard treatments for 50 people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal was to find the right dose and watch for side effects. Researchers also tracked how we…

This phase II trial tested whether a newer antibiotic combination (imipenem-relebactam) works better than standard antibiotics for treating fever caused by low white blood cell counts in cancer patients. About 100 adults with cancer or who had a stem cell transplant took part. Th…

This study tested a personalized geriatric optimization plan (GO!) in 30 adults aged 60 and older who were getting a donor stem cell transplant for blood cancers or bone marrow failure. The plan included tailored advice on diet, sleep, activity, and medications to improve physica…

This study tested a drug called CT-011 (a PD-1 blocker) and a dendritic cell vaccine given after a stem cell transplant in 35 people with multiple myeloma. The goal was to see if this combination is safe and can boost the immune system to fight remaining cancer cells. Researchers…

This study looked at 700 adults up to age 65 with multiple myeloma to see if high-dose therapy with a stem cell transplant works better than standard drug therapy (lenalidomide, bortezomib, and dexamethasone). The goal was to find out which approach delays the cancer from growing…

This phase 2 study tested a weekly dose of the drug carfilzomib combined with two standard chemotherapy drugs (melphalan and prednisone) in 32 elderly patients (65 years or older) with newly diagnosed multiple myeloma. The goal was to find the safest effective dose and see how we…

This phase 3 trial tested whether taking lenalidomide (Revlimid) after an autologous stem cell transplant helps people with myeloma stay in remission longer. Over 600 participants under age 65 who had no signs of progression after transplant were randomly assigned to receive lena…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested a drug called daratumumab combined with dexamethasone in 64 people with multiple myeloma that had stopped responding to three other treatments. The goal was to see how many patients' tumors shrank or disappeared. The treatment is not a cure, but aims to control …

This study tested a combination of thalidomide, bortezomib, and high-dose melphalan followed by a stem cell transplant in 29 patients with advanced multiple myeloma who had already failed one round of treatment. The goal was to find the safest dose of thalidomide and see how well…

This early-stage study tested whether adding a drug called BMS-986004 to standard immune-suppressing medicine could help prevent acute graft-versus-host disease (GVHD) in 45 adults with blood cancers or disorders receiving a stem cell transplant. GVHD occurs when donor immune cel…

This phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…

This study looked at the long-term safety of an oral chemotherapy drug (azacitidine) in 5 adults with blood cancers who had already taken it in earlier studies. Researchers tracked side effects and survival to see if continued treatment was safe. The goal was to monitor risks, no…

This study tested whether adding a drug called vorinostat to the standard combination of lenalidomide and dexamethasone could help patients whose multiple myeloma had stopped responding to lenalidomide. The trial enrolled 25 adults with relapsed or refractory multiple myeloma. Th…

This study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…

This early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …

This early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …

This study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…

This study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…

This study tested whether a hydrochloric acid lock can help treat central line infections in 212 cancer and blood disease patients. The acid solution was placed in the line for 10 minutes, repeated three times, alongside standard antibiotics. The goal was to see if it reduces tre…

This phase 2 trial tested a two-step stem cell transplant approach for 47 patients with high-risk blood cancers like leukemia and lymphoma. The method uses the drug cyclophosphamide to lower the chance of graft-versus-host disease (GVHD), a common complication. The goal was to se…

This early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…

This study tested a new way to treat high-risk multiple myeloma using umbilical cord blood that was expanded in the lab with a molecule called UM171. Nineteen patients received this special transplant to see if it was safe and could help control the disease. The goal is to improv…

This early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…

This study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…

This study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…

This study tested a new drug called daratumumab, given together with two standard treatments (lenalidomide and dexamethasone), in 45 people whose multiple myeloma had returned or stopped responding to prior therapy. The main goal was to check safety and see how many patients resp…

This early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…

This study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…

This phase 2 pilot study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if the treatment could eliminate signs of the dis…

This early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …

This early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…

This completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…

This study tested a therapy called bb2121, made from a patient's own immune cells that are reprogrammed to attack myeloma cells. It included over 300 people with multiple myeloma that had returned or was high-risk. The goal was to see if the treatment could shrink tumors and cont…

This pilot study tested a combined bone marrow and kidney transplant from a partially matched family donor in 10 people with both a blood disorder and chronic kidney disease. The goal was to treat both conditions at once and possibly reduce the need for lifelong anti-rejection dr…

This study tested a combination of four drugs (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) in 15 people whose multiple myeloma had returned or stopped responding to treatment. The goal was to see if this experimental mix could shrink the cancer more effectively than…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This study tested a new way to treat multiple myeloma by starting with just two drugs (bortezomib and dexamethasone) and adding a third (lenalidomide) only if the disease wasn't well controlled. The goal was to see if this step-by-step approach could achieve the same good results…

This early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…

This study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …

This study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…

This early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…

This study tested a new drug called MK-7684A, which combines two immune-boosting medicines (pembrolizumab and vibostolimab), in 192 people with blood cancers like lymphoma and multiple myeloma that had returned or stopped responding to prior treatments. The main goals were to see…

This study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…

This study tested whether a shot under the skin (subcutaneous) works as well as an IV drip for the drug isatuximab in people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. All participants also received standard chemotherapy. The goal was to se…

This early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …

This study tested the drug denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and monitored side effects like low calcium and…

This early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…

This early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…

This early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goal…

This phase 2 study tests whether a new drug called GPC-100, combined with propranolol and with or without G-CSF, can effectively mobilize stem cells in people with multiple myeloma who are preparing for an autologous stem cell transplant. The goal is to see if enough stem cells c…

This early-stage trial tested a new cell therapy called CC-95266 in 130 people with multiple myeloma that had come back or stopped responding to treatment. Participants also received chemotherapy drugs to prepare their bodies for the cell infusion. The main goals were to check sa…

This study tested whether adding the drug isatuximab to a standard two-drug regimen (carfilzomib and dexamethasone) helps people with multiple myeloma that has returned or stopped responding to prior treatments. 302 adults who had already received 1 to 3 prior therapies took part…

This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…

This study tested a new way of giving the drug elranatamab to people with multiple myeloma that came back or didn't respond to treatment. The drug was given as a shot under the skin, starting with low doses and then increasing, with longer breaks between doses over time. The goal…

This early-phase trial tested a new drug called cevostamab in 355 people with multiple myeloma that had returned or stopped responding to other treatments. The main goal was to check the drug's safety and find the right dose. While it may help control the disease, it is not a cur…

This study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…

This study tested a combination of pomalidomide and dexamethasone in 63 patients with multiple myeloma that had returned or stopped responding to treatment, and who had specific high-risk genetic changes. The goal was to see how well the drugs controlled the disease and what side…

This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…

This early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…

This phase 2 trial tested a two-step donor stem cell transplant in 51 people with high-risk blood cancers. The approach uses total-body irradiation and chemotherapy to prepare the body, then infuses donor stem cells and later donor immune cells. The goal is to boost the anti-canc…

This study tested a new version of the chemotherapy drug melphalan (EVOMELA) combined with fludarabine and total body irradiation before a half-matched (haploidentical) stem cell transplant in 43 adults with blood cancers like multiple myeloma. The goal was to see if this approac…

This early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…

This early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…

This early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…

This pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …

This phase 3 trial tested whether giving an individualized dose of antithymocyte globulin (ATG) based on a patient's own drug levels works better than a standard fixed dose. The goal was to reduce graft-versus-host disease (a serious immune reaction) and virus reactivation after …

This early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…

This study looked at 42 people with multiple myeloma that was still present after a stem cell transplant. It compared continuing lenalidomide alone versus adding two other drugs (ixazomib and dexamethasone) to try to eliminate the remaining cancer. The goal was to see which appro…

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…

This phase 2 trial tested a combination of four drugs—elotuzumab, carfilzomib, lenalidomide, and dexamethasone—in 46 people newly diagnosed with multiple myeloma. The goal was to see how many patients achieved a very deep response (stringent complete response or minimal residual …

This completed Phase 2 study tested a combination of three drugs—lenalidomide, bortezomib, and dexamethasone (RVD)—in 46 people newly diagnosed with multiple myeloma. The goal was to see how well the drugs worked before a stem cell transplant. The study measured response rates an…

This study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …

This early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This study tested whether giving two drugs—ixazomib and lenalidomide—in an alternating schedule after a stem cell transplant could safely delay the return of multiple myeloma. Thirty patients who had already received a transplant took part. The main goal was to check for side eff…

This early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…

This study tested different drug combinations in 1,503 adults aged 18-65 with newly diagnosed multiple myeloma. The goal was to see which approach—standard drugs or high-dose chemo with stem cell transplant—works better to delay the cancer's return. Patients received maintenance …

This study tested a drug called elranatamab in 39 Chinese patients with multiple myeloma that had stopped responding to at least three prior treatments. The drug works by helping the immune system attack cancer cells. The goal was to see if it could shrink tumors and control the …

This early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…

This study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.

This early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help gui…

This early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…

This early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …

This early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…

This early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …

This early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…

This phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.

This early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…

This study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.

This study tested a combination of three drugs (pomalidomide, dexamethasone, and carfilzomib) in 25 people with multiple myeloma that had come back or stopped responding to prior treatments. The goal was to find the safest dose and see how well the drugs worked together to contro…

This early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…

This early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…

This early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…

This phase 3 study tested whether adding daratumumab to standard pomalidomide and dexamethasone helps people with relapsed or refractory multiple myeloma live longer without their disease getting worse. 304 adults who had already tried lenalidomide and a proteasome inhibitor took…

This study tested whether a stem cell transplant from a matched donor could improve outcomes for myeloma patients under 65 who had already responded well to their own stem cell transplant. Thirteen patients received a reduced-intensity conditioning regimen followed by the donor t…

This early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…

This study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one tha…

This phase 2 trial tested a three-drug combination (ixazomib, cyclophosphamide, and dexamethasone) in 112 patients with multiple myeloma that had returned or stopped responding to three previous treatments. The goal was to see if adding ixazomib to standard chemotherapy could hel…

This study tested whether giving the drug cyclophosphamide after a stem cell transplant could help prevent a serious complication called graft-versus-host disease (GVHD) in 78 blood cancer patients. The approach aimed to make transplants from less-than-perfect donors as safe and …

This early-stage trial tested a new therapy called FT576, made from specially engineered stem cells that become cancer-fighting immune cells. It was given alone or with another drug, daratumumab, to 31 people with multiple myeloma that had returned or stopped responding to prior …

This early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…

This early-stage study tested a combination of two drugs, acalabrutinib and ACP-319, in 40 people with B-cell cancers such as non-Hodgkin lymphoma, multiple myeloma, and B-cell acute lymphoblastic leukemia. The goal was to check safety and how well the drugs work together. Partic…

This early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …

This early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…

This early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…

This early-phase study tested a new drug combination (duvelisib plus BMS-986345) in 14 people with blood cancers like lymphoma, myeloma, and leukemia. The main goal was to find a safe dose and check for side effects. Researchers also looked at how well the cancer responded after …

This early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…

This study tested a combination of three drugs—pomalidomide, cyclophosphamide, and dexamethasone—in 100 patients with multiple myeloma that had returned after initial treatment. All patients had previously been part of the IFM/DFCI 2009 trial. The goal was to see how many patient…

This early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.

This study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 29 people newly diagnosed with multiple myeloma. The goal was to find the safest high dose of carfilzomib and see how well it clears cancer cells from the body. Researchers measured sid…

This early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…

This study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study looked at 50 patients who needed a stem cell transplant from a partially matched donor but had antibodies that could attack the donor cells. Before transplant, they received a blood purification treatment called protein A immunoadsorption to remove those antibodies, so…

This early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…

This early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…

This early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …

This early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…

This early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…

This early study tested whether removing a specific type of immune cell (regulatory T cells) is safe in 30 people with multiple myeloma undergoing a stem cell transplant. Participants received standard transplant drugs plus a procedure to deplete these cells. The goal was to see …

This early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…

This early-phase trial tested a combination of three drugs—selinexor, carfilzomib, and dexamethasone—in 52 patients with multiple myeloma that had returned or stopped responding to treatment. The main goal was to find the safest dose and check for side effects. Researchers hope t…

This study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…

This study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…

This study tested whether tranexamic acid, a drug that helps blood clot, can lower the risk of serious bleeding or death in people with blood cancers who have dangerously low platelet counts. Over 600 adults receiving chemotherapy or a stem cell transplant were randomly given eit…

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumu…

This early-phase study tested a combination of high dose vitamin C and a low dose of the chemotherapy drug melphalan in 6 patients with multiple myeloma that had stopped responding to other treatments. The main goal was to check safety, and researchers also looked for signs that …

This study tested whether the drug tildrakizumab could help prevent graft-versus-host disease (GVHD) in 51 adults receiving a stem cell transplant for blood cancers. GVHD is a serious complication where donor cells attack the patient's body. The goal was to see if adding tildraki…

This early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…

This study looked at 308 adults getting a stem cell transplant for blood cancer. Researchers compared two antibiotics, ciprofloxacin and levofloxacin, to see which one better prevents bacterial infections after transplant. The goal is to find the best option to keep patients safe…

This phase 3 study compared a three-drug combination (daratumumab, lenalidomide, and dexamethasone) against the standard two-drug regimen (lenalidomide and dexamethasone) in 737 people with newly diagnosed multiple myeloma who could not undergo high-dose chemotherapy and stem cel…

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…

This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…

This phase 2 trial tested a combination of three drugs—ixazomib, cyclophosphamide, and dexamethasone—as a first treatment for multiple myeloma. The goal was to see if this mix works better and causes fewer nerve problems than standard options. Twelve newly diagnosed patients took…

This early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…

This early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …

This early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…

This early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…

This completed study tested a combination of three drugs—bortezomib, lenalidomide, and dexamethasone (VRD)—in 419 newly diagnosed multiple myeloma patients. Some patients also received a stem cell transplant. The goal was to see how well the treatment worked and how long patients…

This early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…

This early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…

This study tested whether a combination of two drugs, cyclophosphamide and abatacept, could lower the risk of chronic graft-versus-host disease (GVHD) after a stem cell transplant in people with high-risk blood cancers. GVHD happens when donor cells attack the patient's body. The…

This study tested a combination of three drugs (pomalidomide, ixazomib, and dexamethasone) with or without a fourth drug (cyclophosphamide) in 66 adults with multiple myeloma that had come back or stopped responding to treatment. The goal was to see how well the treatment control…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This study tested two different drug combinations to collect stem cells from 62 multiple myeloma patients before a stem cell transplant. The goal was to see which method works better and causes fewer side effects. Results could help more patients successfully move forward with tr…

This early-phase trial tested a new drug called Purinostat Mesylate in 29 people with relapsed or refractory B-cell lymphomas, a type of blood cancer. The main goals were to check safety, find the right dose, and see how the drug moves through the body. Researchers hope this drug…

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…

This completed early-phase study tested a new radioactive tracer called 18F-BL40 for PET/CT scans in 10 adults with certain blood cancers (like lymphoma and leukemia). The goal was to see if it safely and accurately detects tumors by targeting a receptor common in many cancers. R…

This study compares two types of PET/CT scans—one using a standard tracer (FDG) and another using a newer tracer (FCH)—to see which detects more bone lesions in people newly diagnosed with multiple myeloma. Twenty participants will receive both scans and an MRI within three weeks…

This completed study looked at whether certain proteins in the blood (called biomarkers) can help predict acute graft-versus-host disease (aGVHD) in 500 patients who had a stem cell transplant for blood cancers. Researchers measured levels of REG3, ST2, IL-6, IL-8, and TNF R ever…

This early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …

This study tested a device called PointCheck that uses light to check for severe neutropenia (low white blood cells) in cancer patients without needing a blood sample. Researchers enrolled 81 adults with blood or breast cancers who were receiving chemotherapy. The main goal was t…

This study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…

This study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…

This phase II trial tested whether giving high doses of cyclophosphamide and bortezomib after a stem cell transplant could prevent graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Twenty-three adults with blood cancers received…

This study tested whether sitagliptin, a diabetes medicine, could prevent acute graft-versus-host disease (GVHD) in 190 adults receiving stem cell transplants from related or unrelated donors. Participants took sitagliptin along with standard GVHD prevention. The main goal was to…

This phase 3 trial tested whether a biologic called IMM-101 could reduce severe respiratory infections, including COVID-19, in cancer patients at higher risk. 195 participants either received three doses of IMM-101 or were simply observed. The goal was to see if the treatment cou…

This study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…

This study tested whether young cancer survivors (ages 15-39) could learn to do acupressure on themselves to reduce fatigue. 42 people who had finished cancer treatment at least three months ago and still felt tired took part. They used a special tool and a phone app to apply pre…

This study looked at whether touch-massage can reduce anxiety in people with blood disorders (like leukemia or lymphoma) who are hospitalized in a sterile, isolated room. Sixty-two patients received three massage sessions, and researchers measured their anxiety levels before and …

This study tested a support program for people caring for a loved one undergoing a stem cell transplant for blood cancer. The program included 8 online sessions over 12 weeks to teach stress management, coping skills, and communication. 17 caregivers took part, and the study chec…

This study explored whether multiple myeloma patients could safely administer the drug Carfilzomib at home instead of always going to the hospital. Nine patients who had already received at least one treatment cycle in the clinic were taught to give themselves the infusion on cer…

This study looked at whether a type of talk therapy called cognitive-behavioral therapy (CBT) can help reduce the severe tiredness that many people feel after a stem cell transplant for blood cancer. 66 adults who had a transplant at least 6 months earlier and still had significa…

This study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…

This study tested whether roasted nux vomica capsules can help with nerve pain caused by the chemotherapy drug bortezomib in multiple myeloma patients. Twenty-two participants took the capsules for six weeks while continuing their regular chemo. Researchers measured changes in ne…

This study tested whether a fencing-based exercise program is practical for adults with leukemia or lymphoma who are receiving intensive treatment in a hospital. The goal was to reduce physical decline caused by long bed rest. Eighty patients were invited to take part, and resear…

This study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…

This study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…

This study tested a structured educational program called the Myeloma Pack for people with multiple myeloma. The goal was to see if it could reduce anxiety and depression and improve quality of life. 85 patients took part while receiving standard cancer treatment. Researchers mea…

This study tested a set of dermo-cosmetic products (hand/foot serum, nail strengthener, dissolving oil, and gloves/slippers) in 20 multiple myeloma patients receiving bispecific antibody therapy. The goal was to see if these natural-based products could prevent or reduce skin and…

This study tested a program to help stem cell transplant survivors who have sexual problems. Participants met with a nurse for three months and got educational materials. The goal was to see if this improved their sexual satisfaction, quality of life, and mood. The study involved…

This study tested an online educational program for cancer patients receiving chemotherapy. The program included video sessions, peer discussions, and digital materials to help with symptom management and emotional coping. Researchers compared 212 patients who used the program to…

This study tested whether mindfulness meditation training could help patients who are undergoing a stem cell transplant and staying in a sterile room. 70 adult patients participated, and the researchers measured their anxiety and sleep quality before and after the meditation prac…

This study tested whether a supervised 8-week exercise program (strength, endurance, and flexibility) could help patients recover after an autologous stem cell transplant. Fifteen adults with blood cancers were randomly assigned to exercise or usual care. The researchers measured…

This study tested a mobile health (mHealth) program designed to help people who have had a stem cell transplant for blood cancer get better sleep. Researchers wanted to see if the program was easy to use and if participants liked it. About 30 survivors, caregivers, and doctors ga…

This study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…

This study looked at whether providing free blood transfusions to blood cancer patients would encourage them to enroll in hospice care earlier. Many patients delay hospice because they need transfusions for symptom relief, but hospices often cannot afford to provide them. The stu…

This study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…

This study tested a monthly online peer support group for young adults (ages 18-39) who had received a stem cell transplant. The group met for one hour over six months, led by a nurse and social worker. The goal was to see if the program was practical and helpful for reducing anx…

This study looked at whether starting supportive care (like meetings with a nurse, psychologist, or dietitian) right after a multiple myeloma diagnosis helps patients feel better compared to waiting 6 months. Twenty patients took part, and researchers measured their quality of li…

This study tested whether neuromuscular electrical stimulation (NMES) can help Veterans with blood cancers maintain physical function and reduce fatigue during stem cell transplant. 46 participants used NMES while in the hospital. The goal was to see if this approach could preven…

This study tested whether montelukast (Singulair), a common asthma drug, can reduce the number and severity of infusion reactions in people receiving monoclonal antibody treatments for blood disorders. Forty adults were given montelukast along with standard premedication before t…

This pilot study tested a 6-session exercise and activity program called Health Through Activity (HTA) in 5 adults with multiple myeloma who were on maintenance therapy and had trouble with daily activities due to their health. The goal was to see if the program was feasible and …

This study tested whether a nasal spray made from rose geranium in sesame oil can improve symptoms of nasal vestibulitis—like dryness, discomfort, bleeding, and scabbing—in cancer patients receiving chemotherapy. Over 100 participants were randomly assigned to use either the rose…

This study tested a type of talk therapy called Acceptance and Commitment Therapy (ACT) for people undergoing stem cell transplants. The goal was to help patients cope with the physical and emotional stress of the procedure, improve their physical function, and possibly shorten h…

This study tested whether giving Darzalex Faspro (a drug for multiple myeloma) at home is practical and satisfactory for patients. Twenty adults with multiple myeloma who were already on a monthly daratumumab regimen received their injections at home. The main goal was to measure…

This study tested whether distance Reiki—a hands-off energy therapy—could improve quality of life and immune function in 30 adults with multiple myeloma who had a stem cell transplant. Participants received real Reiki, fake Reiki, or no extra care. The goal was to see if Reiki he…

This study tested two treatments—laser therapy and ozone gas—to relieve painful mouth sores caused by cancer treatment. Forty adults with head and neck or blood cancers took part. Each received one treatment daily for five days. The goal was to see which therapy better reduced so…

This study tested whether psilocybin, a substance from certain mushrooms, given with therapy could safely reduce anxiety and depression in 55 people with metastatic cancer. Participants received counseling and a pharmaceutical-grade psilocybin dose. The trial focused on safety an…

This study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…

This study tested whether wearing a special cooling cap during chemotherapy can prevent hair loss in people with multiple myeloma getting a stem cell transplant. 31 participants used the Penguin cold caps. The goal was to see if at least 75% of people kept more than half their ha…

This pilot study tested whether acupressure, a noninvasive technique, can help reduce anxiety in patients receiving chemotherapy. Thirty adults undergoing chemo at Mayo Clinic who reported at least mild anxiety were offered a nurse-led acupressure session and taught how to do it …

This study tested whether colesevelam, a drug used for high cholesterol, can safely reduce diarrhea in people with multiple myeloma who take lenalidomide. 25 participants received colesevelam for 4 weeks. The goal was to see if diarrhea improved to a mild level or better. The stu…

This study tested a system that uses electronic health records to help cancer patients track and manage common symptoms like pain, fatigue, anxiety, and sleep problems. Over 50,000 adults with cancer took part. The goal was to see if this approach could improve quality of life an…

This study looked at whether adding heart rate biofeedback training to regular physical activity can improve quality of life for people who have finished treatment for blood cancers. 80 adults in remission took part. The goal was to see if this combination helps them feel better …

This study tested whether doing simple positive activities—like performing a kind act or writing a gratitude letter—could improve quality of life for cancer patients from collectivist cultures (e.g., Latino, Asian American, African American). 75 patients and their caregivers part…

This study tracks 50 people with blood cancers who are receiving CAR T therapy. Researchers will take blood samples over time to measure immune cells and genetic changes. The goal is to find patterns that predict or explain why the cancer comes back. This is an observational stud…

This completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…

This study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…

This study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…

This study looks at how the adrenal glands work in people who are critically ill, such as those with sepsis. Adrenal insufficiency may affect up to 77% of ICU patients, but current tests are not reliable. Researchers will measure hormone levels in 225 participants, including heal…

This study aims to develop a standardized reference guide for pharmacists to use during initial consultations with multiple myeloma patients starting oral chemotherapy. The goal is to provide clear, consistent information that helps patients understand and follow their treatment …

This study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…

This study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…

This study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.

This study looked for a virus called HHV6 in the skin and blood of 37 adults with blood cancers who developed a rash during hospital stays. The goal was to see if the virus is linked to the rash, which could help doctors diagnose and treat the rash more effectively. The study is …

This study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…

This pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.

This completed study looked at 70 patients with myeloma or lymphoma who needed stem cell transplants. Researchers compared two drugs, Zarzio and Granocyte, used to stimulate stem cell production before collection. The goal was to see if one drug led to better stem cell grafts. Si…

This study tested whether providing grocery delivery (via Instacart) and weekly nutrition coaching calls helps cancer survivors who struggle to afford healthy food. Forty survivors who had finished active cancer treatment took part. The goal was to see if this support was practic…

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study tracked 204 patients with blood cancers or those on certain immune-suppressing treatments to see how often COVID-19 infection persists for 21 days or more. Researchers also looked for factors that make a long infection more likely. The goal was to better understand who…

This study looked back at medical records of 100 adults with multiple myeloma that had returned after initial treatment. Researchers compared how long patients stayed cancer-free on four different three-drug combinations. The goal was to see which combination worked best in real-…

This study followed over 900 newly diagnosed multiple myeloma patients who were not eligible for a stem cell transplant. Researchers compared heart-related side effects between those treated with lenalidomide (Revlimid) and those receiving other treatments. The goal was to better…

This completed study looked at how immune cells recover in 61 adults who received a stem cell transplant for blood cancers. Researchers measured the function of T and NK cells by testing their cytokine profiles after stimulation. The goal was to see if these measurements could he…

This completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…

This study monitored 201 people with multiple myeloma to see how well COVID-19 vaccines and boosters work for them. Since their immune systems are weaker, researchers wanted to learn if vaccines still provide good protection. The goal was to find better ways to keep this vulnerab…

This pilot study tested a program called GUIDE, which uses a trained navigator to help cancer patients overcome social and financial barriers to joining clinical trials. The study included 100 adults with cancer who were eligible for a trial and had at least one health-related so…

This study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…

This study interviewed 9 people with multiple myeloma who had received at least 5 different treatments. The goal was to learn about their experiences and what factors are most important to them when deciding on a treatment. No new drugs or therapies were tested; instead, the stud…

This study reviewed medical records of 431 people with smoldering multiple myeloma (SMM), a pre-cancerous condition, to see how the disease progresses over time. Researchers looked at which patients are at higher risk of developing active multiple myeloma and what treatments they…

This study looked at whether it is safe to lower the number of platelets needed before placing a central line (a special IV) in patients with blood disorders. Normally, patients get a platelet transfusion if their count is below 50, but this study tested a lower trigger of 10. Th…

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …

This study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…

This study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…

This study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…

This study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…

This study looked at 182 older adults with blood cancer or lung cancer to see if a special calculator could predict who would have severe side effects from chemotherapy. Researchers measured patients' fitness before and after treatment to better understand how well they could han…

This completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…

This study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…

This study looked at whether an exercise program is practical for people aged 65 and older with blood cancers like lymphoma, leukemia, or myeloma who are about to receive CAR T-cell therapy. The program included remote exercise sessions and was tested with 20 participants to see …

This study tested a program to help older patients (age 60+) with blood cancers plan their future medical care while in the hospital. The program focused on completing advance directives and healthcare proxy forms. Out of 41 participants, the study found that the program was feas…

This study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…

This study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …

This study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…

This study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…

This study looked back at 60 adult blood cancer patients who had stem cell transplants and later developed a rare fungal infection called mucormycosis. Researchers compared cases before COVID-19 (2015-2020) to during the pandemic (2020-2024) to see if the virus, new tests, or new…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study looked at the safety of the drug Ninlaro (ixazomib) when used to treat multiple myeloma in everyday medical practice in China. About 482 patients were observed, and researchers recorded any side effects or dose changes. The goal was to gather real-world safety informat…

This study looked at 70 patients who had a stem cell transplant for blood cancer. Researchers measured levels of complement proteins in the blood to see if they are linked to graft-versus-host disease, a common and serious side effect. The goal is to better understand how inflamm…

This study tested a program called FinFit to help adolescent and young adult cancer survivors deal with money problems caused by their illness. Researchers interviewed 16 people from community cancer clinics to design and improve the program. The goal was to figure out the best w…

This study measured certain proteins in the blood and urine of 20 newly diagnosed multiple myeloma patients before and 30 days after starting daratumumab. The goal was to see if these markers could help detect early kidney injury. Participants provided samples during routine lab …

This Mayo Clinic study tested whether 3D surface images can replace standard CT scans for planning electron radiation therapy. Researchers used plastic models to compare dose accuracy between virtual CTs from 3D scans and real CTs. The goal is to reduce radiation exposure and spe…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study looked at 232 adult cancer patients with sepsis and low blood pressure to see if adding a type of antibiotic called aminoglycosides helps them recover faster. The main goal was to see how quickly their blood pressure returned to normal without needing strong blood pres…

This completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…

This study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…

This study followed 44 adults with leukemia or lymphoma who received CAR T-cell therapy to see how their hearts were affected. Researchers used heart scans, blood tests, and quality-of-life surveys before and after treatment. The goal was to learn how often heart problems occur a…

This study looked at whether newer imaging techniques can better detect when a person with early blood conditions (MGUS or smoldering myeloma) is developing active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an exper…

This study looked at 56 older adults (65+) with multiple myeloma to see if a comprehensive geriatric assessment—a series of questions and tests about physical and mental health—along with blood tests could predict who would have serious side effects from chemotherapy. The goal is…

This study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …

This study looked at 66 people with multiple myeloma to find out how many also have a condition called autoimmune hemolytic anemia (AIHA), where the body attacks its own red blood cells. Researchers measured how common AIHA is in these patients and whether it affects their progno…

This completed study tested whether artificial intelligence and MRI scans could help automate the planning of total marrow irradiation, a type of radiation therapy given before a bone marrow transplant for blood cancers. Researchers aimed to reduce the 10-day planning time and be…

This completed study looked at how common gut inflammation and leaky gut are in 80 adults with blood cancer who were in intensive care for sepsis or septic shock. Researchers measured two markers—calprotectin in stool and zonulin in blood—to better understand intestinal dysfuncti…

This study looked at health records from over 5,700 adults in Japan with sepsis (blood poisoning) to see how many also developed a serious blood clotting disorder called DIC. Researchers collected information from hospital databases to track DIC rates and severity scores. The goa…

This French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…

This study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…

This study looked at how stem cell transplants affect thinking, memory, and daily activities in adults aged 60 to 85 with blood cancer. Researchers measured cognitive function, physical function, and quality of life at several points after transplant. The goal was to understand w…

This study explored whether a simple blood test (liquid biopsy) and a whole-body MRI can detect leftover cancer cells in people with multiple myeloma, potentially replacing the need for a bone marrow biopsy. Researchers enrolled 36 adults with newly diagnosed or previously treate…

This completed study looked at 314 people with blood cancers who received stem cell transplants from mismatched donors. Researchers tracked donor-specific antibodies after transplant to see how often they appear and what factors influence them. The goal is to better understand an…

This study tested whether a small, swallowable capsule can accurately measure body temperature in 30 hospitalized patients with blood cancers who have very low immunity (neutropenia). Researchers compared the capsule's temperature readings to standard ear thermometer measurements…

This study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutra…

This study looked at over 1,200 people in Denmark who had a stem cell transplant for blood diseases, some as far back as 1970. Researchers used detailed surveys to measure late effects and quality of life. The goal is to find out what medical and personal factors help survivors f…

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…

This completed study enrolled 200 cancer patients aged 40-85 who were about to start chemotherapy. Researchers tracked symptoms like numbness, daily activity, and falls using surveys, activity monitors, and even smart socks. The goal was to find simple ways for doctors to predict…

This completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…

This study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…

This completed study looked at whether the COVID-19 vaccine triggers a strong immune response in 146 people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose. The goal was to see if these patients, …

This completed study examined lung CT scans from 148 adults with blood diseases to identify common patterns of lung involvement. Researchers tracked how often certain radiological features appeared and counted complications. The goal was to better understand the range of lung iss…

This study looked at how faithfully adults with multiple myeloma (a type of blood cancer) follow their prescribed carfilzomib combination treatments in everyday medical practice. It included 359 patients who had already tried at least one prior therapy. The goal was to measure ad…

This completed study looked at 800 children who survived blood cancer to see if having a congenital heart defect raises their risk of death or other health problems later in life. Researchers also checked for shared genetic links between the two conditions. The goal is to better …

This study looked at 57 people who had a stem cell transplant for blood cancer. Researchers wanted to see if certain immune cells (iNKT cells) could help predict the risk of graft-versus-host disease (GVHD), a serious side effect. They measured these cells in the blood and the tr…

This study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …

This completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…

This study collected blood, saliva, stool, urine, and skin samples from 19 people with unknown or poorly understood immune system problems. The goal was to learn how different parts of the immune system work together. No treatments or drugs were tested. Participants were followed…

This study looked at whether a substance called M-CSF in the blood can help identify bone lesions in people with multiple myeloma. Researchers compared M-CSF levels in 111 participants: those with multiple myeloma, those with a pre-cancer condition called MGUS, and healthy contro…

This study tested whether a wearable device and smartphone app can monitor cancer patients' vital signs and symptoms as well as standard in-clinic checks. About 100 patients with various cancers participated, either after CAR-T cell therapy or during radiation treatment. The goal…

This study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…

This early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…

This study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …

This study tested whether patients and caregivers find 'Coping Together' manuals helpful after a stem cell transplant. 41 participants shared their thoughts on the manuals during the first 100 days after transplant. The goal was to improve these self-directed coping guides for fu…